Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 529

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Beta Blockers and Breast Cancer Mortality: A Population- Based Study

Barron, Thomas I., Connolly, Roisin M., Sharp, Linda, Bennett, Kathleen, Visvanathan, Kala·2011·Journal of Clinical Oncology

Abstract

Purpose: Preclinical studies have demonstrated that antagonism of β 2 -adrenergic signaling inhibits several pathways necessary for breast tumor progression and metastasis. A series of population-based observational studies were conducted to examine associations between beta blocker use and breast tumor characteristics at diagnosis or breast cancer–specific mortality. Patients and Methods: Linked national cancer registry and prescription dispensing data were used to identify women with a diagnosis of stage I to IV invasive breast cancer between January 1, 2001, and December 31, 2006. Women taking propranolol (β 1 /β 2 antagonist; n = 70) or atenolol (β 1 antagonist; n = 525), in the year before breast cancer diagnosis were matched (1:2) to women not taking a beta blocker (n = 4,738). Associations between use of propranolol or atenolol and risk of local tumor invasion at diagnosis (T4 tumor), nodal or metastatic involvement at diagnosis (N2/N3/M1 tumor), and time to breast cancer–specific mortality were assessed. Results: Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0.24, 95% CI, 0.07 to 0.85) or N2/N3/M1 (OR, 0.20; 95% CI, 0.04 to 0.88) tumor compared with matched nonusers. The cumulative probability of breast cancer–specific mortality was significantly lower for propranolol users compared with matched nonusers (hazard ratio, 0.19; 95% CI, 0.06 to 0.60). There was no difference in T4 or N2/N3/M1 tumor incidence or breast cancer–specific mortality between atenolol users and matched nonusers. Conclusion: The results provide evidence in humans to support preclinical observations suggesting that inhibiting the β 2 -adrenergic signaling pathway can reduce breast cancer progression and mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.5422

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 529

Metadata

Authors
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K.
Venue
Journal of Clinical Oncology
Published
2011-07-01
Volume
29
Issue
19
Pages
2635-2644
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2139731996
Cited by
529
References
32
FWCI
23.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beta Blockers and Breast Cancer Mortality: A Population- Based Study. https://app.cochat.ai/papers/10.1200/jco.2010.33.5422
The paper
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011). Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.5422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.